Tillgänglighet och ekonomi

Access to artificial reproduction technology in the Nordic countries in 2004. Sol Olafsdottir H, Wikland M, Möller A. Acta Obstet Gynecol Scand. 2009; 88(3):301-7.

Economic evaluation of infertility treatment for tubal disease.
Granberg M, Strandell A, Thorburn J, Daya S, Wikland M.
J Assist Reprod Genet. 2003 Aug; 20(8):301-8.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States.
Silverberg K, Daya S, Auray JP, Duru G, Ledger W, Wikland M, Bouzayen R, O’Brien M, Falk B, Beresniak A.
Fertil Steril. 2002 Jan; 77(1):107-13.